MyMD Pharmaceuticals Stock (NASDAQ:MYMD)
Previous Close
$1.82
52W Range
$1.75 - $63.90
50D Avg
$2.00
200D Avg
$5.24
Market Cap
$4.29M
Avg Vol (3M)
$61.81K
Beta
2.69
Div Yield
-
MYMD Company Profile
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
MYMD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GOVX | GeoVax Labs, Inc. |
| GOSS | Gossamer Bio, Inc. |
| XBIO | Xenetic Biosciences, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| LGND | Ligand Pharmaceuticals Incorporated |
| REVB | Revelation Biosciences, Inc. |
| RXRX | Recursion Pharmaceuticals, Inc. |
| REPL | Replimune Group, Inc. |
| SRZN | Surrozen, Inc. |
| YS | LakeShore Biopharma Co., Ltd |
| LYEL | Lyell Immunopharma, Inc. |
| UBX | Unity Biotechnology, Inc. |
| KRON | Kronos Bio, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| PASG | Passage Bio, Inc. |
| ORIC | ORIC Pharmaceuticals, Inc. |
| KROS | Keros Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| AVIR | Atea Pharmaceuticals, Inc. |
| KZR | Kezar Life Sciences, Inc. |
| EXAI | Exscientia plc |
| LYRA | Lyra Therapeutics, Inc. |
| NVCT | Nuvectis Pharma, Inc. |